Article · 29 Dec 2025
Conference abstractPublished 26 Jun 2017
Assessment of bioequivalence between two formulations of Salmeterol xinafoate/Fluticasone propionate HFA pMDI 25/250 mcg per actuation in healthy volunteers
Sitec Labs Pvt Ltd., India Cipla Ltd., Mumbai, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Salmeterol xinafoate and fluticasone propionate has been shown to be effective and well tolerated in the treatment of asthma. Our research aimed to determine the bioequivalence between two formulations (test and reference) of salmeterol xinafoate/ fluticasone propionate HFA pMDI 25/250 mcg per actuation with and without charcoal blockade. Study-1 was a single dose, randomized, 4-period, 2-sequence, laboratory-blinded, crossover replicate design conducted in 42 healthy volunteers under fasting conditions with concurrent oral charcoal administration (to block gastrointestinal absorption). Study-2 was a single dose, randomized, 2-period, 2-sequence, laboratory-blinded, crossover design conducted in 74 healthy volunteers under fasting conditions without concurrent oral charcoal administration. Both the studies had a minimum washout period of 14 days. Blood samples were collected up to 18 hours post-dose and 36 hours post-dose for pharmacokinetic profiling for study-1 and 2 respectively. Safety evaluations included monitoring adverse events and vital signs as well as clinical laboratory assessments. Plasma concentrations of salmeterol xinafoate and fluticasone propionate were determined using a validated LCMS/ MS method. The 90% CI of the difference between the test and reference for salmeterol xinafoate was 94.10-113.20, and 96.44-116.69 for Cmax, and AUC0-t respectively in study-1. The 90% CI of the difference between the test and reference for salmeterol xinafoate was 83.44-100.29 and 104.08-120.08 and for fluticasone propionate was 91.08-105.07, and 99.86-115.61 for Cmax, and AUC0-t respectively in study-2. Since the 90% CI for Cmax and AUC0-t was within the 80-125% interval in both the studies, it was concluded that test and reference formulations of salmeterol xinafoate/fluticasone propionate HFA pMDI 25/250 mcg per actuation are bioequivalent in their rate and extent of absorption with and without charcoal blockade.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Muneesh Garg”
- BylineArticles whose byline prints “Raghu Naidu”
- BylineArticles whose byline prints “Krishnan Iyer”
- BylineArticles whose byline prints “Ratnakar Jadhav”
- BylineArticles whose byline prints “Amolkumar Birhade”
- BylineArticles whose byline prints “Juliet Rebello”
- BylineArticles whose byline prints “Nazma Morde”
- BylineArticles whose byline prints “Mayuri Mangale”
